- Artiva Biotherapeutics (ARTV, Financial) presents promising Phase 1/2 data for AlloNK® in treating B-cell non-Hodgkin lymphoma.
- Key findings include prolonged duration of response and deep B-cell depletion, demonstrating meaningful clinical progress.
- AlloNK® shows a well-tolerated safety profile and potential for broader accessibility in community settings.
Artiva Biotherapeutics, Inc. (ARTV), a clinical-stage biotechnology company, announced that it will present new, longer-term Phase 1/2 data for its AlloNK® (AB-101) therapy at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting. This data pertains to relapsed/refractory B-cell non-Hodgkin lymphoma and demonstrates a prolonged duration of response, significant B-cell depletion, and a favorable safety profile for AlloNK when used in combination with rituximab.
The findings suggest that AlloNK, when combined with rituximab, can enhance antibody-dependent cellular cytotoxicity, offering a potential improvement over traditional lymphoma treatments. The safety profile of AlloNK indicates its suitability for wider use beyond specialized centers, potentially increasing patient access to this innovative therapy.
Additionally, Artiva will present data on the manufacturing scalability and consistency of AlloNK, addressing common limitations in the cell therapy space. This progress is crucial for the commercial viability and accessibility of cell therapies.
The presentations are scheduled for the ASGCT meeting in New Orleans, Louisiana, from May 13-17, 2025. The details of these presentations will be available on the ASGCT website and subsequently on Artiva's website under the "Scientific Posters & Publications" section of the “Events & Presentation” page.
